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1 |  INTRODUCTION
Primary biliary cholangitis (PBC), formerly known as pri-
mary biliary cirrhosis, is an autoimmune inflammatory disor-
der of the liver which causes progressive destruction of small 
bile ducts. The disease is rare with an incidence of 4.9 cases 
per 100 000 person-years.1 PBC mostly affects middle-aged 
women, and many cases (20%-60%) are asymptomatic with 
incidental diagnosis due to abnormal laboratory findings. 
The most common presenting symptoms are fatigue and pru-
ritus.2 As hyperlipidemia is a common laboratory finding 
along with the abnormal liver profile, PBC has been hypoth-
esized to increase the risk of cardiovascular and atheroscle-
rotic complications. However, several studies have shown 
that PBC is not associated with increased risk of cardiovascu-
lar events, especially stroke.3-6 We report a case of a woman 
who presented with acute ischemic stroke and subsequent 
diagnosis of PBC. The patient demonstrated hyponatremia 
secondary to extreme hypercholesterolemia with signifi-
cantly elevated high-density lipoprotein cholesterol (HDL-C) 
levels, an unusual presentation of PBC. To our knowledge, 
no other cases of acute stroke and/or extremely high HDL-C 
have been associated with PBC.
2 |  CASE PRESENTATION
A 52-year-old woman with no known chronic medical condi-
tions presented to the emergency department with left lower 
extremity weakness, left facial droop, and slurred speech for 
3 days. The patient also reported diffuse body pruritus, yel-
low skin, and dark urine for 7 days. She denied any history 
of stroke or other cardiovascular diseases, diabetes, hyperlipi-
demia, liver disease, exposure to hepatitis, alcohol abuse, or 
intravenous drug use. She had a family history of lupus in her 
maternal grandmother and two aunts. Body mass index was 
26.63 kg/m2. Physical examination was remarkable for scle-
ral icterus and xanthelasma of bilateral medial lower eyelids 
(Figure 1). Neurological examination demonstrated left fa-
cial weakness, decreased strength (4 of 5) of left upper and 
lower extremities, and decreased rapid repetitive movement 
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Abstract
Primary biliary cholangitis is associated with hyperlipidemia, but studies show 
that the condition does not increase cardiovascular risks. The case presents acute 
ischemic stroke with no underlying risk factors and subsequent new diagnosis of 
primary biliary cholangitis, which can suggest possible association between primary 
biliary cholangitis and acute stroke.
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with ataxic finger-to-nose testing on the left side. Laboratory 
tests were remarkable for increased aspartate aminotransferase 
(AST) (93 IU/L), alanine aminotransferase (ALT) (115 IU/L), 
total bilirubin (10.4 mg/dL), direct bilirubin (5.0 mg/dL), and 
alkaline phosphatase (ALP) (838 IU/L). Computed tomogra-
phy (CT) of the head and subsequent magnetic resonance im-
aging of the brain both revealed acute thalamic infarction of 
the right side with no evidence of hemorrhagic stroke (Figure 
2). Ultrasonography of the abdomen showed mild spleno-
megaly with no evidence of gallstones or biliary dilatation. 
CT of the abdomen showed no evidence of biliary obstruc-
tion or active hepatocellular disease except incidentally found 
hepatic hemangioma. The patient was admitted to the hospi-
tal and started on aspirin 81 mg and rosuvastatin 20 mg for 
acute thalamic stroke management. Bilateral carotid duplex 
test showed 1%-19% stenosis of left proximal internal carotid 
artery (ICA) and right bulb, but no stenosis in right ICA or 
left bulb. Echocardiogram showed no evidence of intracardiac 
shunts. The patient's neurological symptoms subsequently re-
solved with minimal residual deficits.
Further workup was performed for hepatic manifes-
tations. Magnetic resonance cholangiopancreatography 
showed patent intrahepatic and extrahepatic bile ducts in-
cluding common bile duct with no evidence of focal stric-
ture or filling defect. Antimitochondrial antibody titer was 
high at >1:320. Based on the diagnostic criteria from the 
American Association for the Study of Liver Diseases,7 
PBC was diagnosed. The patient was started on ursodiol 
3.25 mg/kg three times daily.
During the hospital course, the patient's serum sodium 
remained low at around 119 mmol/L. Lipid profile demon-
strated extremely high total cholesterol at 2018  mg/dL, 
extremely high HDL-C at >200 mg/dL (low-density lipopro-
tein-C [LDL-C] not calculated), and increased triglycerides 
at 319 mg/dL. Corrected serum sodium level reflecting hy-
percholesterolemia using the equation developed by Dimeski 
et al8 was 124 mg/dL. Serum osmolality (293 mOsm/kg) and 
urine sodium (68 mmol/L) were normal, and urine osmolal-
ity (233 mOsm/kg) was slightly decreased. The hyponatremia 
was thought to be pseudohyponatremia secondary to extreme 
hypercholesterolemia. The patient was started on rosuvasta-
tin 20 mg, fenofibrate 145 mg, and ezetimibe 10 mg for hy-
percholesterolemia and was discharged.
The patient is currently under evaluation for liver transplan-
tation with no evidence of decompensated liver failure. Patient 
has finished physical therapy and speech therapy sessions 
F I G U R E  1  Picture of the patient's face. It reveals bilateral 
scleral icterus and xanthelasmas on the medial side of bilateral lower 
eyelids (arrows). This picture is used under permission with a direct 
written consent from the patient
F I G U R E  2  Radiologic studies of the brain. (A) Computed tomography scan of the brain showing 1.5-cm lucency involving the right 
thalamus, which potentially suggests acute infarct as one of the differentials. (B) T1-weighted magnetic resonance imaging that shows increased 
focal density involving right thalamic area. (C) Diffusion-weighted magnetic resonance imaging which demonstrates an area of acute infarct in the 
right thalamus measuring approximately 2.1 × 1.3 cm2 in the greatest dimension
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since the stroke and shows functional improvement. She has 
been taking ursodiol 300 mg three times daily and rosuvastatin 
10 mg once daily. Her most recent liver profiles have improved 
with AST 34 IU/L, ALT 38 IU/L, total bilirubin 1.0 mg/dL, and 
ALP 181  IU/L. Her total cholesterol and serum sodium also 
improved at 267 mg/dL and 140 mg/dL, respectively. LDL-C 
and HDL-C became 179 mg/dL and 68 mg/dL, respectively.
3 |  DISCUSSION
Our patient with PBC presented with acute thalamic stroke, 
hypercholesterolemia with extremely high HDL-C levels, 
and possibly pseudohyponatremia. Studies have concluded 
that PBC has no significant association with circulatory sys-
tem-related mortality9 or increased risk of myocardial infarc-
tion, stroke, or transient ischemic attack.4,6 Our case shows 
that further longitudinal research is needed regarding stroke 
risk and PBC.
Hypercholesterolemia causes atherosclerosis through 
endothelial injury and dysfunction from inflammatory cy-
tokines and oxidation of LDL particles. As high cholesterol 
in PBC is primarily due to increased lipoprotein-X which is 
an abnormal LDL particle that inhibits oxidation of normal 
LDL particles, it has been hypothesized that hyperlipidemia 
in PBC might have a protective effect for atherosclerosis.10,11 
Floreani et al supported this hypothesis by suggesting that 
increased adiponectin levels in PBC patients might work as 
a protective factor against atherosclerosis.12 However, a sys-
tematic review showed that PBC significantly increases the 
risk of CAD.13 Our patient had extreme hypercholesterolemia 
with very high HDL-C levels. Three possible mechanisms 
have been suggested by which PBC causes hypercholester-
olemia. First, diminished bile acid synthesis due to cholesta-
sis in PBC downregulates hepatic cholesterol synthesis. This 
leads to progressive decline in LDL receptors, which subse-
quently can increase serum LDL cholesterol. Second, PBC 
causes decreased intestinal cholesterol absorption, which can 
result in decreased bile acid synthesis and subsequent poor 
micellar solubilization. Third, cholestasis largely results in 
increased serum lipoprotein-X which can originate from ei-
ther reflux of biliary lipids into plasma or the accumulation 
of phospholipid and free cholesterol in serum due to reduced 
lecithin:cholesterol acyltransferase activity.11 As the hyper-
lipidemia in PBC mostly comes from increased lipoprotein-X 
which is an LDL derivative, most of the case reports regard-
ing PBC and hypercholesterolemia showed normal or slightly 
elevated HDL-C levels.14-18 Interestingly, our case shows ex-
tremely elevated HDL-C which presented with acute stroke. 
It has been well established that HDL-C level is inversely as-
sociated with cardiovascular events. However, recent studies 
show that extremely high HDL-C can cause adverse results. 
Madsen et al found U-shaped association between HDL-C 
level and all-cause mortality and concluded that extremely 
high HDL-C paradoxically increases all-cause mortality.19 
Hirata et al also demonstrated association of extremely high 
HDL-C with increased atherosclerotic cardiovascular disease 
(including CAD and stroke) mortality.20 Although there is 
no clear explanation for the association of extremely high 
HDL-C and cardiovascular mortality, investigators suggested 
a possible genetic variant such as cholesterylester transfer 
protein (CETP) gene mutation. CETP gene is known to be 
responsible for HDL-C metabolism, and its polymorphism 
has been suggested to be associated with accelerated athero-
sclerosis and cardiovascular risk.21 As our patient developed 
acute ischemic stroke with no underlying risk factors but ex-
tremely high HDL-C, further studies regarding the associa-
tion of extremely high HDL-C and cardiovascular risks are 
needed.
Our patient also demonstrated significant hyponatre-
mia, which was thought to be pseudohyponatremia in the 
setting of extreme hypercholesterolemia. In marked hyper-
lipidemia, the sodium concentration per unit of plasma is 
reduced because the water fraction falls below 80% even 
though the total sodium concentration in the water phase 
is unchanged.22
A limitation of our report was the lack of equipment 
to perform lipoprotein electrophoresis, which would 
have helped to delineate what proportion of lipoprotein 
was significantly increased, especially with regard to 
lipoprotein-X.
In conclusion, our case represents possibly the first re-
port of a patient with newly diagnosed PBC presenting with 
acute ischemic stroke with no other risk factors of athero-
sclerosis. Even though studies have shown that PBC does 
not increase the risk of atherosclerotic complications, we 
suggest appropriate monitoring, counseling, or appropriate 
treatment for possible stroke when caring for patients with 
PBC. Additional studies will be needed regarding the asso-
ciation of extremely high HDL-C and the risk of cardiovas-
cular complications.
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